MEET THE EXPERTS ALL PROGRAMMES DEVELOPED COLLABORATIONS CONTACT

Patient case reports: from diagnosis to treatment of TRK-fusion positive cancer

Dr Philipp Ivanyi, Assoc. Prof. Caterina Marchiò, Prof. David Hong

On-demand educational resources (e-learning, videos and slide site) are now available following a successful NTRK CONNECT Experts Knowledge Share event delivering practical insights and experiences on the diagnosis and treatment of TRK fusion-positive cancer. A number of adult cancer cases were discussed including lung cancer, GI cancer, sarcoma and thyroid cancer.

Dr Philipp Ivanyi

Medical Oncologist

Hannover Medical School

Germany

Assoc. Prof. Caterina Marchiò

Pathologist

University of Turin

Italy

Prof. David Hong

Medical Oncologist

MD Anderson Cancer Center, Houston

United States (US)

Biography Disclosures

Dr Philipp Ivanyi

Medical Oncologist

Hannover Medical School

Germany

Dr Ivanyi is the Assistant Medical Director Hematology, Oncology, Hemostasis, Stem Cell Transplantation (Palliative Care) at the Hanover Medical School. He is also Head of the Clinical Trial Unit for Medical Oncology

Dr Ivanyi also serves as:

Steering Committee and Spokesman, Immune Cooperative Oncology Group, Comporehensive Cancer Center, Claudia von Schelling Center (CCC-H)
Board Member, Clinical Trial Steering Committee, CCC-H
Spokesman Interdisciplinary Working Group Kidney Cancer, Germany Cancer Society (IAGN-DKG)

His research interests include clinical and experimental Research in Urogenital Cancer, Head and Neck Cancer, Sarcoma, Rare Cancers, Targeted Therapies. He has >80 SCI Publication and has a depth of experience in >50 Clinical Trials Phase I – IV (PI and Country Lead).

Dr Philipp Ivanyi has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AIM, AIO, Apogepha, Astella, Astra Zeneca, Bayer, BMS, ClinSol, Deciphera, Deutsche Gesellschaft für Thoraxchirurgie, DKG-Onkoweb, EISAI, EMD-Serono, EUSA, FoFM, GSK, Id-Institut, Ipsen (Europe), Lilly, MedKom, Metaplan, MedWiss, Merck Serono (Global), MSD, MTE-Academy, New Concept Oncology, Niedersächsische Krebsgesellschaft, Novartis, Onkowissen-tv.de, Pharma Mare, Pfizer, Roche, Schmitz-Communikation, Solution Academy,Stiftung Immunonkologie, StreamedUP!, ThinkWired!, Vivantis and Wilhelm Sander Stiftung.

Biography Disclosures

Assoc. Prof. Caterina Marchiò

Pathologist

University of Turin

Italy

Dept. of Medical Sciences - University of Turin Pathology Unit, FPO-IRCCS Candiolo Cancer Institute, strada provinciale 142, 10060 Candiolo Caterina Marchiò, MD PhD, obtained her medical degree at The University of Turin graduating summa cum laude in 2004. She completed her PhD in 2008 after working in collaboration between the University of Turin and the Breakthrough Breast Cancer Research Centre at the Institute of Cancer Research in London between 2006 and 2008. Upon completion of the residency in Pathology at the University of Turin she visited as a Research Scholar the Department of Pathology at Memorial Sloan Kettering Cancer Centre in New York in 2014. She joined the faculty at the University of Turin as an Assistant Professor of pathology at the end of 2014 and she was appointed Associate Professor of Pathology in 2018. Between 2017 and 2018 she served as Visiting Professor at the Pathology Department of Institut Curie in Paris, as a Mayent-Rotschild grantee. Prof. Caterina Marchiò is a diagnostic and experimental pathologist at the Pathology Unit of FPO-IRCCS Candiolo Cancer Institute (University of Turin). Her routine diagnostic activity focuses on breast pathology and molecular diagnostics of solid tumors, including sign-out for in situ hybridization, DNA sequencing and RNA-based assays applied to diagnostics. Her research interests span from histopathogenesis of breast carcinomas to molecular pathology of special histologic types of breast cancer and genetics of HER2-positive carcinomas. A specific interest in HER2-equivocal breast cancer has been funded by the Italian Association of Cancer Research (AIRC), Regione Piemonte and the Ministry of University, Education and Research. She has also actively worked on the standardization of the preanalytical conditions in Pathology to ensure optimal tissue preservation and quality of DNA, RNA and antigens. She is part of the SPIDIA4P consortium, funded by the European Community (H2020-SC1-2016-2017, EU project 733112 – “SPIDIA4P - SPIDIA for Personalized Medicine).

Assoc. Prof. Caterina Marchiò has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Astrazeneca, Bayer, Roche and Daiichi Sankyo.

Biography Disclosures

Prof. David Hong

Medical Oncologist

MD Anderson Cancer Center, Houston

United States (US)

Dr David S. Hong is a Professor, Deputy Chairman in the Department of Investigational Cancer Therapeutics (Phase I Program), Clinical Medical Director of the Clinical Translational Research Center (CTRC), and Associate Vice President of Clinical Research at The University of Texas MD Anderson Cancer Center.

Dr Hong was instrumental in forming one of the largest and most innovative Phase 1 clinical trial units in the world, with over 1300 patients enrolled in clinical trials in FY2021 and over 400 active ongoing clinical trials.

Dr Hong has been the Principal Investigator of over 120 research protocols that involve a wide range of sponsors, including the Cancer Therapy Evaluation Program (CTEP) at the National Cancer Institute. He has published over 374 publications in Peer-reviewed Journals such as NEJM, Lancet Oncology, JCO and Nature.

He has been involved in the early development of cabozantinib, siltuximab, dabrafenib, trametinib, regorafenib, lenvatinib, larotrectinib, tesotumab vendotin, and sotorasib the first drug to target KRAS that have led to FDA approval.

He has also helped found 2 companies OncoResponse and Telperian.

He is an expert on c-Met, NTRK, KRAS, and adoptive cellular therapy in solid tumors and has led several national trials such as the c-Met amplified, c-Met exon 14 deleted, and NTRK arms of the NCI-MATCH trial. He been awarded the ASCO Young Investigator Award, the Jesse Jones award, Best Boss award at MD Anderson, Irwin Krakoff Award for Clinical Research, and the Gerald P. Bodey award for education and Mentor of the year award in the Division of Cancer Medicine, MD Anderson.

Prof. David Hong has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AbbVie, Adaptimmune, Adlai-Nortye, Amgen, Astra-Zeneca, Bayer, Bristol- Myers Squibb, Daiichi-Sankyo, Deciphera, Eisai, Endeavor, Erasca, F. Hoffmann- LaRoche, Fate Therapeutics, Genentech, Genmab, Ignyta, Infinity, Kite, Kyowa Kirin, Lilly, LOXO, Merck, Medimmune, Mirati, Mologen, Navier, NCI-CTEP, Novartis, Numab, Pfizer, Pyramid Bio, SeaGen, Takeda, TCR2, Teckro, Turning Point Therapeutics and VM Oncology.

Assoc. Prof. Caterina Marchio: A lung cancer case

time E-learning | open 15 min |accreditation: EACCME | Nov 2022

This programme was made for you: your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

download resources

Download slides PDF

Download slides PPTX

This programme was made for you: your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

Prof. David Hong: Lung cancer, sarcoma and GI cancer

time E-learning | open 15 min |accreditation: EACCME | Nov 2022

This programme was made for you: your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

This programme was made for you: your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

Dr Philipp Ivanyi: A thyroid cancer case

time E-learning | open 20 min |accreditation: EACCME | Nov 2022

This programme was made for you: your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

This programme was made for you: your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

Patient case reports: from diagnosis to treatment of TRK-fusion positive cancer

The key clinical takeaways from this accredited e-learning are:

There are a range testing approaches and diagnostic algorithms available to identify patients with TRK fusion-positive cancers
Practical guidance is available on how to test for NTRK fusions in many cancers including lung, sarcoma, GI and thyroid cancer
The two first-generation TRK inhibitors, larotrectinib and entrectinib, have demonstrated robust efficacy and safety in many cancers

Take the e-learning and claim your CME credit.

This course has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) and ECMEC® is available. Through an agreement between the European Union of Medical Specialists (UEMS) and the American Medical Association (AMA), physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™.

PRECISION ONCOLOGY CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from AstraZeneca and Bayer.

Other programmes of interest

Prof. Dimitrios Tsakiris

Dr Lars Asmis

Podcast

2 min

Cancer and Thrombosis

Sep 2023

Dr Elisa Agostinetto

Prof. Valentina Guarneri

Interactive patient case

15 min

Oral SERDs: New Endocrine Therapy Options in ER+ Advanced or Meta...

Sep 2023

Prof. Chee-Kiat Tan

Publication

5 min

Surveillance and Diagnosis of HCC in Asia: Poster Presentation at...

Sep 2023

Assoc. Prof. Gerald Prager

Video

4 min

Long-term Response in Advanced Colorectal Cancer

Sep 2023

Prof. Dr Jeroen Dekervel

Dr Amit Singal

Podcast

29 min

A New Era in Treating Patients with Advanced HCC

Sep 2023

Dr Jaume Capdevila

Asst. Prof. Mauro Cives

Micro learning

30 min

Accreditation: EACCME

Recognising, Diagnosing and Managing Neuroendocrine Tumours

Aug 2023

Acromegaly and Neuroendocrine Tumours Global Survey

Publication

15 min

Acromegaly and Neuroendocrine Tumours Global Survey

Aug 2023

Prof. Shaheenah Dawood

Assoc. Clinical Professor Rena Callahan

Podcast

74 min

Oral SERDs in ER+ Breast Cancer

Aug 2023

Dr Tracy L Stockley

Prof. David Hong

Podcast

24 min

An Introduction to Molecular Testing

Jul 2023

Dr Neal Shore

Dr Andrew J. Armstrong

Video

10 min

Clinical Implementation of Testing and PARPi as Monotherapy or in...

Aug 2023

Janet Forgenie

Video

3 min

Nursing Support for mCRPC Patients During Radiopharmaceutical Tre...

Jul 2023

Prof. Andrea Sartore-Bianchi

Video

5 min

Conference Update: ASCO and WCGIC 2023

Jul 2023

Other programmes developed by Assoc. Prof. Caterina Marchiò

Assoc. Prof. Caterina Marchiò

Pathologist

University of Turin

Italy

Portrait of Caterina Marchio and Christian Rolfo

Prof. Christian Rolfo

Assoc. Prof. Caterina Marchiò

Podcast

20 min

Podcast: TRK fusion-positive lung cancer

Jan 2022

Assoc. Prof. Caterina Marchiò

5 min

NTRK CONNECT Update from ESMO 2019

2019

Prof. Ulrik Lassen

Assoc. Prof. Caterina Marchiò

5 min

Learn about the patient journey through diagnosis and treatment o...

Dec 2020

Other programmes developed by Prof. David Hong

Prof. David Hong

Medical Oncologist

MD Anderson Cancer Center, Houston

United States (US)

Dr Tracy L Stockley

Prof. David Hong

Podcast

24 min

An Introduction to Molecular Testing

Jul 2023

Prof. David Hong

5 min

TRK fusion-positive cancer poster tour at ESMO 2022

Oct 2022

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.